Metronidazole B Braun

Metronidazole, the active ingredient in Metronidazole B Braun, is a nitroimidazole antibiotic presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and selected protozoal infections in adults and children as prescribed.

GNH USA supplies Metronidazole B Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metronidazole is used to manage infections caused by anaerobic bacteria and certain protozoa. - Anaerobic bacterial infections: reduces bacterial load and improves clinical symptoms in mixed anaerobic infections. - Clostridioides difficile infection: eradicates toxin‑producing C. difficile, aiding resolution of colitis. - Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic overgrowth. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving genital symptoms. - Amebic liver abscess: destroys Entamoeba histolytica trophozoites, facilitating abscess resolution.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional throbbing headache. - Diarrhea: loose stools during therapy. - Abdominal pain: cramping or discomfort. - Dizziness: light‑headed feeling.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate care. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis, rash, or swelling. - Stevens‑Johnson syndrome: serious skin eruption. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Neutropenia: reduced white blood cell count increasing infection risk.

Metronidazole requires careful use in specific patient groups and conditions. - Renal impairment: adjust dosing and monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Alcohol consumption: avoid during and 48 hours after therapy to prevent disulfiram‑like reaction. - Pregnancy and lactation: assess risk–benefit; limited safety data available. - Concurrent anticoagulants: monitor coagulation parameters for enhanced effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: increased anticoagulant effect; monitor INR closely. - Lithium: elevated lithium levels; monitor for toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma concentrations. - Cimetidine: may increase metronidazole levels, enhancing side effects. - Phenobarbital: may decrease metronidazole efficacy through enzyme induction.